title: The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers.
abstract: We report the safety, biodistribution, and internal radiation dosimetry of a new PET tracer, (18)F-AH111585, a peptide with a high affinity for the alpha(v)beta(3) integrin receptor involved in angiogenesis.
  
  
  METHODS
  PET scans of 8 healthy volunteers were acquired at time points up to 4 h after a bolus injection of (18)F-AH111585. (18)F activity in whole blood and plasma and excreted urine were measured up to 4 h after injection. In vivo (18)F activities in up to 12 source regions were determined from quantitative analysis of the images. The cumulated activities subsequently calculated were then used to determine the internal radiation dosimetry, including the effective dose.
  
  
  RESULTS
  Injection of (18)F-AH111585 was well tolerated in all subjects, with no serious or drug-related adverse events reported. The main route of (18)F excretion was renal (37%), and the 3 highest initial uptakes were by liver (15%); combined walls of the small, upper large, and lower large intestines (11%); and kidneys (9%). The 3 highest absorbed doses were received by the urinary bladder wall (124 microGy/MBq), kidneys (102 microGy/MBq), and cardiac wall (59 microGy/MBq). The effective dose was 26 microGy/MBq.
  
  
  CONCLUSIONS
  (18)F-AH111585 is a safe PET tracer with a dosimetry profile comparable to other common (18)F PET tracers.
authors.affiliation: Medical Diagnostics, GE Healthcare Ltd., Amersham, Buckinghamshire, England. brian.mcparland@ge.com
authors.forename: Brian J
authors.initials: BJ
authors.lastname: McParland
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Miller
authors.forename: Terence J
authors.initials: TJ
authors.lastname: Spinks
authors.forename: Laura M
authors.initials: LM
authors.lastname: Kenny
authors.forename: Safiye
authors.initials: S
authors.lastname: Osman
authors.forename: Mandeep K
authors.initials: MK
authors.lastname: Khela
authors.forename: Eric
authors.initials: E
authors.lastname: Aboagye
authors.forename: Raoul C
authors.initials: RC
authors.lastname: Coombes
authors.forename: Ai-Min
authors.initials: AM
authors.lastname: Hui
authors.forename: Pamela S
authors.initials: PS
authors.lastname: Cohen
mesh_terms: D000368:Aged; D001120:Arginine / Q000737:chemistry; D001224:Aspartic Acid / Q000737:chemistry; D001384:Azetidines / Q000493:pharmacokinetics*; D005260:Female; D005998:Glycine / Q000737:chemistry; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography / Q000379:methods*; D011725:Pyridines / Q000493:pharmacokinetics*; D011829:Radiation Dosage; D011874:Radiometry / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D014018:Tissue Distribution
chemical_list: C119803:2-fluoro-3-(2-azetidinylmethoxy)pyridine; D001384:Azetidines; D010455:Peptides; D011725:Pyridines; D019275:Radiopharmaceuticals; D001224:Aspartic Acid; D001120:Arginine; D005998:Glycine